Syndax Pharmaceuticals has filed a patent for a method of treating cancer and other diseases mediated by the menin-MLL interaction. The patent involves administering a combination of a menin inhibitor and a CYP3A4 inhibitor to the individual in need of treatment. GlobalData’s report on Syndax Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Syndax Pharmaceuticals, cancer treatment biomarkers was a key innovation area identified from patents. Syndax Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Combination treatment for cancer using menin and cyp3a4 inhibitors
A recently filed patent (Publication Number: US20230165858A1) describes a method of treating individuals in need by administering a combination of a menin inhibitor and a CYP3A4 inhibitor. Menin inhibitors can be selected from Formula (I) and Formula (II), and the CYP3A4 inhibitor can be chosen from a group of compounds including boceprevir, nefazodone, clarithromycin, and others. The patent also mentions that the menin inhibitor and the CYP3A4 inhibitor can be administered in separate dosage forms or in a combined dosage form.
The patent further discusses the administration of the menin inhibitor in a sub-therapeutically-effective amount, while the CYP3A4 inhibitor is administered in a therapeutically-effective amount. Alternatively, the CYP3A4 inhibitor can also be administered in a sub-therapeutically-effective amount. The menin inhibitor and the CYP3A4 inhibitor can be administered concurrently, simultaneously, essentially simultaneously, or within the same treatment protocol. They can also be administered sequentially, with the combination being administered for an initial treatment period followed by continued administration of the menin inhibitor.
In addition to the method of treatment, the patent also describes a kit for treating cancer, which includes a combination of a menin inhibitor and a CYP3A4 inhibitor. The kit may also include instructions on how to use it. Furthermore, the patent discusses a composition of a menin inhibitor and a CYP3A4 inhibitor, where the two substances come into contact with each other in the human body. The composition can be prepared by bringing the menin inhibitor and the CYP3A4 inhibitor into contact with each other at a specific locus.
The patent also mentions the use of a strong CYP3A4 inhibitor in the method of treatment. Finally, the patent describes a specific method for treating cancer in a patient, which involves administering posaconazole and the menin inhibitor of Formula (II) or a pharmaceutically acceptable salt thereof. The menin inhibitor can be a fumarate salt or a sesquifumarate salt.
Overall, this patent provides a method and compositions for treating individuals in need, particularly for cancer treatment, by combining a menin inhibitor and a CYP3A4 inhibitor. The patent covers various aspects of the treatment, including the administration methods, dosage forms, and the use of specific inhibitors.
To know more about GlobalData’s detailed insights on Syndax Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
